Viking Therapeutics (VKTX) News Today

Viking Therapeutics, Inc. (NASDAQ: VKTX) is seeing a mixed investor reaction as progress in its obesity-drug pipeline competes with concerns about rising costs, widening losses and insider selling. The stock remains focused largely on clinical milestones because Viking has no approved products and is not generating meaningful revenue.

• Positive Sentiment: Viking said its Phase 3 VANQUISH 1 and 2 trials of injectable VK2735 in obesity are fully enrolled and advancing. The company expects maintenance-dosing data in the third quarter and plans to begin Phase 3 testing of oral VK2735 in the fourth quarter of 2026. Management believes the pill could become the first oral dual GLP-1 agonist to reach the market, providing important potential catalysts. Viking Therapeutics second-quarter corporate update
• Positive Sentiment: The company ended the second quarter with approximately $502 million in cash and equivalents, giving it substantial funding for its clinical programs. Viking also reported that its Phase 1 study of the amylin agonist VK3019 is underway, expanding its metabolic-disease pipeline.
• Positive Sentiment: Viking reported a second-quarter loss of $1.10 per share, narrower than the consensus estimate of a $1.21 loss. The earnings beat may provide some support, although it has limited significance for a pre-revenue biotechnology company. Viking Therapeutics second-quarter results
• Neutral Sentiment: Analyst and financial-media coverage remains broadly optimistic, with several reports highlighting VKTX as a high-risk, high-reward obesity-drug opportunity. However, these reports do not represent a new major rating change or clinical result. Wall Street bull case for Viking Therapeutics
• Negative Sentiment: Viking’s net loss widened to $128.1 million from the prior-year period as research and development spending increased. Revenue was essentially unchanged, underscoring the company’s dependence on future clinical success and eventual commercialization.
• Negative Sentiment: CEO Brian Lian, CFO Greg Zante and COO Marianna Mancini sold shares worth roughly $4.95 million, $710,000 and $610,000, respectively. The filings said the transactions covered tax withholding tied to equity vesting, which reduces their negative signal, but the sizable insider sales may still weigh on sentiment. Viking Therapeutics insider transactions